[Evaluation of prazosin in the treatment of benign hypertrophy of the prostate. A case-control study].

Abstract

A control-case study conducted in 56 patients, all diagnosed with benign prostate hypertrophy of which 36 were Prazosin-treated patients and the remaining 20 were controls. The patient's mictional signs and symptoms as well as flow parameters were monitored at 3 and 6 months, respectively. We conclude that Prazosin is an alpha-blocker useful in early prostate disorders and when no obstructive urological disease is present.

• Authors: M Adriazola Semino, E García Cobo, I De la Calle Muñoz, E Tejeda Bañez, F Romero
• Journal: Actas urologicas espanolas (Actas Urol Esp) Vol. 17 Issue 7 Pg. 402-4 (Jul 1993) ISSN: 0210-4806 [Print] Spain
• Vernacular Title: Valoración del Prazosín en el tratamiento de la hipertrofia benigna de próstata. Estudio caso-control.
• PMID: 7690177 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Prazosin

Topics

• Aged
• Aged, 80 and over
• Case-Control Studies
• Humans
• Male
• Middle Aged
• Prazosin (therapeutic use)
• Prostatic Hyperplasia (drug therapy)